

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

DISCLOSEABLE TRANSACTION IN RELATION TO LEASE AGREEMENTS

On July 31, 2026 (after trading hours), MP CardioFlow, a wholly-owned subsidiary of the Company, entered into the Lease Agreement I with the Landlord, pursuant to which MP CardioFlow agreed to lease from the Landlord the Property I for a period of five years, commencing on August 1, 2026 and ending on July 31, 2031, both days inclusive.

On July 31, 2026 (after trading hours), MicroPort CRM Shanghai, a wholly-owned subsidiary of the Company, entered into the Lease Agreement II with the Landlord, pursuant to which MicroPort CRM Shanghai agreed to lease from the Landlord the Property II for a period of five years, commencing on August 1, 2026 and ending on July 31, 2031, both days inclusive.

As the highest applicable percentage ratio under Rule 14.07 of the Listing Rules in respect of the value of the right-of-use asset recognized by the Group under the Lease Agreements, on an aggregated basis, pursuant to HKFRS 16 is more than 5% but less than 25%, the Lease Agreements constitute discloseable transactions for the Company subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules.

THE LEASE AGREEMENTS

The Lease Agreement I

On July 31, 2026 (after trading hours), MP CardioFlow, a wholly-owned subsidiary of the Company, and the Landlord entered into the Lease Agreement I in relation to the leasing of the Property I.

Subject matter and terms of the Lease Agreement I

MP CardioFlow will lease from the Landlord the Property I with area of approximately 9,042.09 sq.m. for a term of five years, commencing on August 1, 2026 and ending on July 31, 2031, both days inclusive.

Use of the Property I

The Property I will be used by the Group for the production of the Company's heart valvular products and related supporting facilities.

Rent

The aggregate rent payable by MP CardioFlow under the entire term of the Lease Agreement I is approximately RMB90.76 million, which was determined by the parties after arm's length negotiations with reference to the prevailing market rents of comparable properties. MP CardioFlow and the Landlord have agreed that if, after the actual commencement of the lease, the rental level of the area where the leased premises are located fluctuates significantly, the parties may, upon mutual negotiation and agreement, adjust the rent in accordance with the prevailing market rental level of the same area.

The rent will be settled monthly by cash in advance. As the Landlord designed and constructed the Property I in accordance with the operational requirements of the Company, a deposit equivalent to one year's rent, which is approximately RMB18.15 million in aggregate shall be payable to the Landlord as security under the Lease Agreement I. Given that MP CardioFlow has paid a security deposit of RMB28.70 million to the Landlord under the 2021 Lease Agreement (as defined below), the difference of RMB10.54 million will be refunded to the Group by way of offsetting against rental payments. The security deposit will be refunded without interest upon expiry of the lease term or the termination of the Lease Agreement I.

Management fees and utility charges

MP CardioFlow bears the management fees, water, electricity and other utility charges of the Property I directly to the suppliers of such services. The aforesaid charges payable by MP CardioFlow may be paid by the Landlord on its behalf, or by MP CardioFlow itself based on the actual usage amount.

The Lease Agreement II

On July 31, 2026 (after trading hours), MicroPort CRM Shanghai, a wholly-owned subsidiary of the Company, and the Landlord entered into the Lease Agreement II in relation to the leasing of the Property II.

Subject matter and terms of the Lease Agreement II

MicroPort CRM Shanghai will lease from the Landlord the Property II with area of approximately 4,634.95 sq.m. for a term of five years, commencing on August 1, 2026 and ending on July 31, 2031, both days inclusive.

Use of the Property II

The Property II will be used by the Group for the production of the Company's cardiac rhythm management products and related supporting facilities.

Rent

The aggregate rent payable by MicroPort CRM Shanghai under the entire term of the Lease Agreement II is approximately RMB46.52 million, which was determined by the parties after arm's length negotiations with reference to the prevailing market rents of comparable properties. MicroPort CRM Shanghai and the Landlord have agreed that if, after the actual commencement of the lease, the rental level of the area where the leased premises are located fluctuates significantly, the parties may, upon mutual negotiation and agreement, adjust the rent in accordance with the prevailing market rental level of the same area. The Board does not expect that such adjustment to the rent will be so significant as to resulting in a change in the classification of the lease under Chapter 14 of the Listing Rules.

The rent will be settled monthly by cash in advance. As the Landlord designed and constructed the Property II in accordance with the operational requirements of the Company, a deposit equivalent to one year's rent, which is approximately RMB9.30 million in aggregate will be payable to the Landlord as security under the Lease Agreement II. Given that, pursuant to the previous agreement between MicroPort CRM Shanghai and the Landlord (expired prior to the effective date of the Lease Agreement II), MicroPort CRM Shanghai has paid a security deposit of RMB 15.21 million to the Landlord, the remaining balance of RMB5.91 million will be refunded to the Group by way of offsetting against rental payments. The security deposit will be refunded without interest upon expiry of the lease term or the termination of the Lease Agreement II.

Management fees and utility charges

MicroPort CRM Shanghai bears the management fees, water, electricity and other utility charges of the Property II directly to the suppliers of such services. The aforesaid charges payable by MicroPort CRM Shanghai may be paid by the Landlord on its behalf, or by MicroPort CRM Shanghai itself based on the actual usage amount.

INFORMATION ON THE PROPERTIES

Each of the Property I and Property II is part of purpose-built industrial facilities developed by the Landlord, which is located at No. 1661, Zhangdong Road and No. 2585 Zuchongzhi Road, the China (Shanghai) Pilot Free Trial Zone (中國(上海)自由貿易試驗區張東路1661號) with gross floor area of approximately 9,042.09 sq.m. and 4,634.95 sq.m., respectively.

REASONS FOR AND BENEFITS OF THE LEASE AGREEMENTS

The Properties were purpose-built facilities for the operation of the Group. Following the completion of construction, the Group commenced leasing the Properties and entered into relevant lease agreement in May 2021 for its production use which was expired prior to the effective date of the Lease Agreements (the “**2021 Lease Agreement**”). For details, please refer to the Company’s announcements dated May 13, 2021 and June 11, 2021. The Group intended to continue to use the Properties for production purposes in support of its expansion plan. The continued leasing of the Properties was beneficial and essential to the Company’s daily production activities, ensuring operational stability and supporting the Group’s ongoing business development.

As the rent for the Lease Agreements was determined with reference to prevailing market rate and that the terms of the Lease Agreements were concluded based on normal commercial terms, the Directors are of the view that the Lease Agreements were entered into on normal commercial terms and that the terms of which are fair and reasonable and are in the interests of the Company and the Shareholders as a whole.

INFORMATION ON THE PARTIES

The Company, MP CardioFlow and MicroPort CRM Shanghai

The Company is incorporated in the Cayman Islands with limited liability. The Company is a global leader in innovation within the field of structural heart intervention and cardiac rhythm management dedicated to providing physicians and patients with innovative, full-cycle heart failure health management services and building a leading enterprise of emerging technologies in cardiac diagnosis and therapy.

MP CardioFlow is a limited liability company established in the PRC and is a wholly-owned subsidiary of the Company. It is principally engaged in the research and development, manufacturing, and commercialization of heart valve devices.

MicroPort CRM Shanghai is a limited liability company established in the PRC on May 30, 2013 and a wholly-owned subsidiary of the Company. It is principally engaged in the research and development, manufacturing, and commercialization of cardiac rhythm management products.

The Landlord

The Landlord, an Independent Third Party, is a limited liability company established in the PRC and is principally engaged in investment management, investment consulting, production and sales of precision machinery, biomedical intermediates (except medicine), research and development of high-tech products and related technical services, import and export of goods and technology, leasing of non-residential properties and property management. It is an indirect subsidiary of Real & Realistic Foundation Limited (“**Real & Realistic**”), an Independent Third Party. To the best knowledge of the Company, Real & Realistic is a company limited by guarantee with no share capital incorporated in Hong Kong. It is a charity foundation that focuses on advancing and promoting science and education and has no beneficial owners and ultimate controllers. The current directors of Real & Realistic are Mr. Chen Wei (陳偉), Mr. Xu Binkai (徐彬凱) and Mr. Wang Decai (王德才), each an Independent Third Party. Real & Realistic through its subsidiaries has invested directly in certain subsidiaries and equity-accounted investees of MicroPort®. To the best knowledge of the Directors, Real & Realistic also holds less than 2.2% of the issued share capital of the Company.

IMPLICATIONS UNDER THE LISTING RULES

In accordance with HKFRS 16 “Leases”, the Group shall recognise the value of the right-of-use asset on the statement of financial position in connection with the lease of the Properties. Therefore, the lease of the Properties under the Lease Agreements is regarded as one-off acquisition of capital asset of the Group. Based on the preliminary estimation of the Company, the value of the right-of-use assets recognized by the Group under each of the Lease Agreement I and the Lease Agreement II is approximately RMB78.47 million and RMB40.23 million, which is calculated based primarily on the present value of the total base rent payable by the Group during the term of the Lease Agreements. As the highest applicable percentage ratio under Rule 14.07 of the Listing Rules in respect of the value of the right-of-use asset recognized by the Group under the Lease Agreements, on an aggregated basis, pursuant to HKFRS 16 is more than 5% but less than 25%, the Lease Agreements constitute discloseable transactions for the Company subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules.

DEFINITIONS

In this announcement, the following expressions shall have the meanings set out below unless the context requires otherwise:

“Board”	the board of directors of the Company;
“Company”	MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司), a company with limited liability incorporated under the laws of the Cayman Islands on January 10, 2019;

“connected person”	has the meaning ascribed to it under the Listing Rules;
“Director(s)”	the director(s) of the Company;
“Group”	the Company and its subsidiaries;
“HKFRS 16”	Hong Kong Financial Reporting Standard 16 “Leases” issued by the Hong Kong Institute of Certified Public Accountants;
“Independent Third Party”	person who is not a connected person of the Group;
“Landlord”	Shanghai BlueOrange Capital Corp. (上海回青橙投資管理有限公司), (formerly known as Shanghai We’TRON Capital Corp. (上海微創投資管理有限公司)), the landlord of the Properties;
“Lease Agreement I”	the lease agreement entered into between MP CardioFlow and the Landlord;
“Lease Agreement II”	the lease agreement entered into between MicroPort CRM Shanghai and the Landlord;
“Lease Agreements”	Lease Agreement I and Lease Agreement II;
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time;
“MicroPort®”	MicroPort Scientific Corporation (微創醫療科學有限公司), an exempted company incorporated in the Cayman Islands with limited liability whose shares are listed on the Main Board of the Stock Exchange (stock code: 00853);
“MicroPort CRM Shanghai”	MicroPort Soaring CRM (Shanghai) Co., Ltd. (創領心律管理醫療器械(上海)有限公司), a limited liability company established in the PRC on May 30, 2013 and a wholly-owned subsidiary of the Company;
“PRC”	the People’s Republic of China;
“Property I”	the property lease from the Landlord by MP CardioFlow under the Lease Agreement I;
“Property II”	the property lease from the Landlord by MicroPort CRM Shanghai under the Lease Agreement II;

“Properties”	Property I and Property II, the industrial facilities located at the Shanghai Free Trade Trial Zone, the details of which are summarized in the section headed “Information on the Properties” of this announcement;
“RMB”	Renminbi, the lawful currency of the PRC;
“MP CardioFlow”	Shanghai MicroPort CardioFlow Medtech Co., Ltd. (上海微創心通醫療科技有限公司), a limited liability company established in the PRC on May 21, 2015 and a wholly-owned subsidiary of the Company;
“Shareholders”	shareholders of the Company;
“sq.m.”	square meters;
“Stock Exchange”	The Stock Exchange of Hong Kong Limited; and
“%”	per cent.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, August 2, 2026

As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang and Mr. Deng Aoyi, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang, Dr. Hu Bingshan and Mr. Mao Junxiang.